Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL.

Abstract:

INTRODUCTION:One of the causes of long-term morbidity associated with the treatment of acute lymphoblastic leukemia (ALL) is late neurotoxicity manifesting as impairment of higher cognitive functions. Cranial radiation therapy (CRT) and chemotherapeutic agents, particularly methotrexate (MTX), are often suggested to be major contributing factors for its development. Homocysteinemia that arises as a result of MTX-induced folate depletion was proposed to play a role in MTX-related neurotoxicity. Several enzymes are essential to maintain the homocysteine levels. Their different functional forms, associated with common genetic polymorphisms, may modulate homocysteine levels and thereby influence MTX-associated neurotoxicity. OBJECTIVES:To test this hypothesis we assessed whether the variants of the methylene tetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), cystathionine beta-synthase (CBS) and endothelial nitric acid synthase (eNOS, NOS3) genes, acting either independently or in conjunction with other risk factors, influenced the cognitive functioning in ALL patients. The influence of the genes was measured by estimating the change in IQ scores over a period of 4 years post ALL diagnosis. RESULTS:Two variants, the CBS 844ins68 polymorphism and NOS3 894T homozygosity, were associated with a change in IQ scores (p = 0.01 and 0.007, respectively). A multivariate model obtained through step-wise selection pointed to the importance of the NOS3 894TT genotype only. This effect appears to be dependent on CRT; IQ decline was apparent among individuals with the 894TT genotype who received radiation therapy (p = 0.03). Furthermore, additional factors affecting IQ were identified, including the treatment administered (i.e., CRT; p = 0.02) and a younger age at diagnosis (p = 0.003), and the modifying effect of the treatment protocols was also noted (p = 0.04). CONCLUSION:The results suggest that NOS3 genotyping might identify individuals that are susceptible to intellectual impairment following ALL treatment.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Krajinovic M,Robaey P,Chiasson S,Lemieux-Blanchard E,Rouillard M,Primeau M,Bournissen FG,Moghrabi A

doi

10.1517/14622416.6.3.293

keywords:

subject

Has Abstract

pub_date

2005-04-01 00:00:00

pages

293-302

issue

3

eissn

1462-2416

issn

1744-8042

journal_volume

6

pub_type

杂志文章
  • Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.

    abstract:UNLABELLED:Glutathione S-transferases (GSTs) participate in the detoxification of chemotherapeutic agents. Genetic polymorphisms in GST genes (GSTP1 Ile105Val, copy-number variants of GSTM1 and GSTT1) that lead to diminished enzyme activity have been associated with increased chemotherapeutic treatment benefit in color...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.132

    authors: Funke S,Timofeeva M,Risch A,Hoffmeister M,Stegmaier C,Seiler CM,Brenner H,Chang-Claude J

    更新日期:2010-01-01 00:00:00

  • Rapid and reliable screening of HLA-B*15:02 in four Chinese populations using single-tube multiplex real-time PCR assay.

    abstract:AIM: HLA-B*15:02 screening should be performed to prevent antiepileptic drug induced severe cutaneous adverse reactions in populations of Asian origin. This study aimed to develop fast and reliable HLA-B*15:02 genotyping method and to investigate the distribution of HLA-B*15:02 in different Chinese ethnicities. MATERI...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0041

    authors: Wang H,Kang X,Zhou S,Chen R,Liu Z,Han M,Chen C,Gong Y

    更新日期:2017-06-01 00:00:00

  • Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer.

    abstract::Aim: To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP). Patients & Methods: Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0049

    authors: Gagno S,Bartoletti M,Romualdi C,Poletto E,Scalone S,Sorio R,Zanchetta M,De Mattia E,Roncato R,Cecchin E,Giorda G,Toffoli G

    更新日期:2020-09-01 00:00:00

  • Genetic variation in statin intolerance and a possible protective role for UGT1A1.

    abstract::The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin int...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0146

    authors: V Willrich MA,Kaleta EJ,Bryant SC,Spears GM,Train LJ,Peterson SE,Lennon VA,Kopecky SL,Baudhuin LM

    更新日期:2018-01-01 00:00:00

  • Microarray expression technology: from start to finish.

    abstract::The recent introduction of new microarray expression technologies and the further development of established platforms ensure that the researcher is presented with a range of options for performing an experiment. Whilst this has opened up the possibilities for future applications, such as exon-specific arrays, increas...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.1.123

    authors: Elvidge G

    更新日期:2006-01-01 00:00:00

  • Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients.

    abstract:AIM:Genetic variants contribute to statins' therapeutic variability. SREBF-SCAP pathway is a key player in lipid homeostasis. Hence, effect of SREBF-SCAP polymorphisms on therapeutic response was studied. PATIENTS & METHODS:Metabolic syndrome patients of either sex were prescribed rosuvastatin 10 mg for 24 weeks. Clin...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章

    doi:10.2217/pgs-2017-0181

    authors: Rafeeq MM,Habib HS,Murad HAS,Gari MA,Gazzaz ZJ

    更新日期:2018-02-01 00:00:00

  • Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.

    abstract::In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.44

    authors: Awada Z,Zgheib NK

    更新日期:2014-04-01 00:00:00

  • Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.

    abstract::Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0055

    authors: Zuiverloon TC,Theodorescu D

    更新日期:2017-08-01 00:00:00

  • Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.

    abstract:AIMS:S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. We evaluated the association between CYP2A6 polymorphisms and treatment outcome in metastatic gastric cancer patients treated with S-1 plus docetaxel. MATERIALS & METHODS:Chemonaive patients received S-1 40 mg/...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.48

    authors: Kong SY,Lim HS,Nam BH,Kook MC,Kim YW,Ryu KW,Lee JH,Choi IJ,Lee JS,Park YI,Kim NK,Park SR

    更新日期:2009-07-01 00:00:00

  • The impact of HER2 overexpression on the miRNA and circRNA transcriptomes in two breast cell lines and their vesicles.

    abstract::HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0182

    authors: Galli de Amorim M,Branco G,Valieris R,Tarcitano E,Tojal da Silva I,Ferreira de Araújo L,Noronha Nunes D,Dias-Neto E

    更新日期:2019-05-01 00:00:00

  • Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients.

    abstract::This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2018-0046

    authors: Frias M,Rivero-Juárez A,López-López P,Rivero A

    更新日期:2018-08-01 00:00:00

  • Drug-induced liver injury: insights from genetic studies.

    abstract::Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not report...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.111

    authors: Andrade RJ,Robles M,Ulzurrun E,Lucena MI

    更新日期:2009-09-01 00:00:00

  • Pharmacogenetic aspects in treatment of colorectal cancer--an update.

    abstract::Pharmacogenomic analyses will become crucial to predict patients' toxicity to treatment and will also help to predict the tumor response. Processes of drug metabolism, drug efflux, DNA-repair and characteristics of drug targets are critical checkpoints of drug efficacy. These crucial pathways for drug action have been...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.4.6.767.22825

    authors: Stoehlmacher J,Goekkurt E,Lenz HJ

    更新日期:2003-11-01 00:00:00

  • Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.

    abstract:AIM:Cytidine deaminase (CDA) irreversibly deaminates cytarabine (Ara-C), a key component of acute myeloid leukemia (AML) induction and consolidation therapy. CDA overexpression results in Ara-C resistance, while decreased expression is associated with toxicity. We evaluated factors influencing variation in CDA mRNA exp...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.149

    authors: Abraham A,Varatharajan S,Abbas S,Zhang W,Shaji RV,Ahmed R,Abraham A,George B,Srivastava A,Chandy M,Mathews V,Balasubramanian P

    更新日期:2012-02-01 00:00:00

  • Gastric cancer pharmacogenetics: progress or old tripe?

    abstract::Gastric cancer remains the second most frequent cause of cancer-related mortality. While surgery is traditionally the initial treatment for early-stage disease, the addition of chemotherapy has been shown to significantly increase overall survival and progression-free survival in advanced and metastatic stages of dise...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.88

    authors: Patel JN,Fuchs CS,Owzar K,Chen Z,McLeod HL

    更新日期:2013-07-01 00:00:00

  • Pharmacogenomic biomarkers for personalized medicine.

    abstract::Pharmacogenomics examines how the benefits and adverse effects of a drug vary among patients in a target population by analyzing genomic profiles of individual patients. Personalized medicine prescribes specific therapeutics that best suit an individual patient. Much current research focuses on developing genomic biom...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.75

    authors: Chen JJ,Lin WJ,Chen HC

    更新日期:2013-06-01 00:00:00

  • Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia.

    abstract::Childhood acute lymphoblastic leukemia survival rates have increased remarkably during last decades due, in part, to intensive treatment protocols. However, therapy resistance and toxicity are still two important barriers to survival. In this context, pharmacoepigenetics arises as a tool to identify new predictive mar...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0164

    authors: Umerez M,Garcia-Obregon S,Martin-Guerrero I,Astigarraga I,Gutierrez-Camino A,Garcia-Orad A

    更新日期:2018-03-01 00:00:00

  • Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation.

    abstract:UNLABELLED:Aim & patients & methods: This study investigated 24-h pharmacokinetic and CYP3A5 pharmacogenetic differences between once-daily tacrolimus (Tac-q.d.) versus twice-daily tacrolimus (Tac-b.i.d.) pretransplantation and at 1 month and 1 year post-transplantaion. RESULTS:The dose-adjusted trough level (Cmin) an...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.98

    authors: Satoh S,Niioka T,Kagaya H,Numakura K,Inoue T,Saito M,Komine N,Narita S,Tsuchiya N,Habuchi T,Miura M

    更新日期:2014-08-01 00:00:00

  • Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.

    abstract::Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS). OCT alleles were investigated in PCOS patients to identify genetic 'bad responders' and 'nonresponders' to metformin including their possible effects on glucose metabolism without treatment. We genotyped eight SNPs in OCT1, OCT2...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.223

    authors: Schweighofer N,Lerchbaum E,Trummer O,Schwetz V,Pieber T,Obermayer-Pietsch B

    更新日期:2014-02-01 00:00:00

  • ALK gene alterations in cancer: biological aspects and therapeutic implications.

    abstract::ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors. Recently, a shortly accumulated biomedical research clarified the numerous biological processes underlying its ability to support cancer development, growth and pro...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0166

    authors: Palmirotta R,Quaresmini D,Lovero D,Silvestris F

    更新日期:2017-02-01 00:00:00

  • Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine.

    abstract:AIMS:To determine the extent of pharmacogenomics instruction at US and Canadian medical schools, characterize perceptions of curricular coverage, identify curricular resources and compare responses with similar studies conducted in US pharmacy schools and British medical schools. MATERIALS & METHODS:A survey was sent ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.122

    authors: Green JS,O'Brien TJ,Chiappinelli VA,Harralson AF

    更新日期:2010-09-01 00:00:00

  • Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarrays. 22-24 January 2001, Zurich, Switzerland.

    abstract::Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

    journal_title:Pharmacogenomics

    pub_type:

    doi:10.1517/14622416.2.1.73

    authors: Jain KK

    更新日期:2001-02-01 00:00:00

  • Investigation of the impact of an ADCY2 polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran.

    abstract::High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0058

    authors: Aghabozorg Afjeh SS,Shams J,Hamednia S,Boshehri B,Olfat A,Omrani MD

    更新日期:2020-09-01 00:00:00

  • Pharmacogenomics of glinides.

    abstract::Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Glinides stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in the p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.152

    authors: Chen M,Hu C,Jia W

    更新日期:2015-01-01 00:00:00

  • Pharmacogenetics in clinical practice: how far have we come and where are we going?

    abstract::Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.52

    authors: Johnson JA

    更新日期:2013-05-01 00:00:00

  • Fibrate pharmacogenomics: expanding past the genome.

    abstract::Fibrates are a medication class prescribed for decades as 'broad-spectrum' lipid-modifying agents used to lower blood triglyceride levels and raise high-density lipoprotein cholesterol levels. Such lipid changes are associated with a decrease in cardiovascular disease, and fibrates are commonly used to reduce risk of ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0140

    authors: House JS,Motsinger-Reif AA

    更新日期:2020-03-01 00:00:00

  • Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

    abstract::Choline phospholipid metabolism is altered in a wide variety of cancers. The choline metabolite profile of tumors and cancer cells is characterized by an elevation of phosphocholine and total choline-containing compounds. Noninvasive magnetic resonance spectroscopy can be used to detect this elevation as an endogenous...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.7.1109

    authors: Glunde K,Serkova NJ

    更新日期:2006-10-01 00:00:00

  • SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis.

    abstract:AIM:Approximately a third of newly diagnosed epilepsy patients do not respond to antiepileptic drugs (AEDs). Evidence suggests that low penetrance variants in the genes of drug targets such as voltage-gated sodium channels may be involved in drug responsiveness. To examine this hypothesis, we compared data from two epi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析,多中心研究

    doi:10.2217/pgs.13.104

    authors: Haerian BS,Baum L,Kwan P,Tan HJ,Raymond AA,Mohamed Z

    更新日期:2013-07-01 00:00:00

  • Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

    abstract::In the growing field of genomics, the utility of returning certain research results to participants has become a highly debated issue. Existing guidelines are not explicit as to the kind of genomic information that should be returned to research participants. Moreover, very few current recommendations and articles in ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.50

    authors: Korol S,Hurlimann T,Godard B,de Denus S

    更新日期:2013-04-01 00:00:00

  • Epigenetics of cancer progression.

    abstract::Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.2.215

    authors: Vucic EA,Brown CJ,Lam WL

    更新日期:2008-02-01 00:00:00